BRCA1:  To Test or Not to Test, That is the Question by Singer, PhD., Mendel E. & Cebul, M.D., Randall D.
Health Matrix: The Journal of Law-
Medicine
Volume 7 | Issue 1
1997
BRCA1: To Test or Not to Test, That is the
Question
Mendel E. Singer, PhD.
Randall D. Cebul, M.D.
Follow this and additional works at: https://scholarlycommons.law.case.edu/healthmatrix
Part of the Health Law and Policy Commons
This Article is brought to you for free and open access by the Student Journals at Case Western Reserve University School of Law Scholarly Commons.
It has been accepted for inclusion in Health Matrix: The Journal of Law-Medicine by an authorized administrator of Case Western Reserve University
School of Law Scholarly Commons.
Recommended Citation
Mendel E. Singer, PhD. and Randall D. Cebul, M.D., BRCA1: To Test or Not to Test, That is the Question, 7 Health Matrix 163 (1997)
Available at: https://scholarlycommons.law.case.edu/healthmatrix/vol7/iss1/11
ARTICLE
BRCA1: TO TEST OR NOT TO
TEST, THAT IS THE QUESTION
Mendel E. Singer, Ph.D.'
Randall D. Cebul, M.D.tt
YOU ARE A PHYSICIAN. This morning, you received a
call from one of your regular patients who sounded very dis-
tressed. Mrs. X, a thirty-five year old Ashkenazi-Jewish wom-
an, tells you she wants to be tested for the BRCA1 gene muta-
tion that she understands can predict the eventual development
of breast cancer. She heard from friends that Ashkenazi-Jewish
women are at especially great risk. She also says that she
wants testing immediately because she does not want to wait
until it is "too late." Besides, she wants to put her fears of
breast cancer to rest. What do you tell her? How can you help
her to make an informed decision about having the test per-
formed?
Because of the great media attention surrounding recent
findings about the prevalence of the BRCA1 gene mutation in
the Ashkenazi-Jewish community, different forms of this sce-
nario has been repeating itself around the country. In the above
vignette, there are numerous questions that must be addressed
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before an informed decision can be made.
Some of these questions have their foundations in clinical
medicine and its basic sciences. Others relate to the interest of
other persons and forces in Mrs. X's environment. And still
others are of a very personal nature to Mrs. X, including her
attitudes towards risk and uncertainty, as well as her personal
views of her health and bodily and psychological well-being.
Fundamental to asking these questions is the understanding
that Mrs. X must make a decision. At its most superficial level,
the decision involves a choice to undergo BRCA1 testing or
not. At a slightly deeper level, the decision implies an accep-
tance of the consequences of her choice. This may include
facing other decisions about further testing and/or preventive
treatment. For example, for women believed to be at an excep-
tionally high risk of breast cancer, the term "preventive treat-
ment" typically involves the surgical removal of both breasts
(prophylactic mastectomy) while they remain disease-free.
Other approaches include using experimental medications (such
as a drug called tamoxifen). The nature of Mrs. X's decision,
relatively simple at first blush, quickly becomes complicated.
Some questions that you and she must consider include the
following:
1. If she has a positive (abnormal) test, would she consid-
er prophylactic mastectomy and/or tamoxifen?
2. How effective is prophylactic mastectomy (or
tamoxifen) in preventing breast cancer? Would she need to
undergo treatment now, or could she wait? Would her insur-
ance pay for it? If not, how much is treatment and follow-up
likely to cost?
3. What are the chances that she will have a positive test?
What would a positive test mean in terms of the chances that
she will develop breast cancer, and when?
4. Would a positive test carry a stigma? Would it hinder
her employment opportunities? Would it affect her ability to
obtain life, health care or disability insurance? How would it
affect her marriage?
5. Are there any reasonable alternatives to obtaining the
BRCA1 test now?
6. Does she have a religious perspective that might be a
factor in deciding whether or not to have the test?
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I. DECISION ANALYSIS
One approach to examining choices such as those faced by
Mrs. X is to use decision analysis. Decision analysis is a struc-
tured approach to examining decisions which have inherent
uncertainty or competing risks. Decision analysis has been used
increasingly in the medical and health care policy community
over the past two decades. This methodology has a number of
advantages. For example, decision analysis does the following:
1) it helps make sure that all relevant components of the deci-
sion are included; 2) it helps make sense of all the pieces of
information and how they interrelate; 3) it allows for and esti-
mates the impact of uncertainty in the data; and 4) it is easily
updated and re-analyzed as more information becomes avail-
able.
Before applying this approach to the decision of whether
to be tested for the BRCA1 mutation, it might be best to brief-
ly discuss what decision analysis is.' A decision analysis has
three main parts: a graphical component, a decision tree, and
an analytic component. The process begins with a graphical
model of the relevant decisions and outcomes. The flow of
decisions and outcomes is represented by lines, called branch-
es. The point where a decision is made is called a decision
node or a choice node, and is represented by a box. Outcomes
emanate from chance nodes, shown as circles. They are called
chance nodes because the different outcomes, or events, have
an associated probability of the event occurring. Endpoints are
called terminal nodes and are depicted as a left-pointing trian-
gle. Following a path from left to right you can trace a series
of decisions and events, culminating in some endpoint. As an
example, Figure 1 is a simple decision tree for treating some
hypothetical ailment. The original decision is whether to treat
with drugs, surgery, or not to treat at all. Surgery may or may
not succeed, and may result in operative death. The endpoint is
life status at some time in the future, for example, one year.
1. See generally MILTON C. WEINSTEIN & HARVEY V. FINEBERG, CLINICAL DECISION
ANALYSIS (1980) (providing an in-depth treatment of decision making analysis).
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The graphical representation helps to ensure an accurate model
that correctly captures the interrelationship of the otherwise
disjointed components of the decision process. It also forces
the decision maker to consider the possibility of adverse out-
comes, as well as successful outcomes, for all choices.
The analytic component comes into play when probabili-
ties are assigned to the chance events. In the hypothetical ex-
ample, surgery leads to a chance node with three possible
outcomes. An analysis will require the assignment of probabili-
ties to each of the three outcomes. Probabilities for a decision
tree might be based on clinical trials, analysis of hospital re-
cords, analysis of claims data, or expert opinion. After assign-
ing all of the required probabilities, probability theory can be
invoked to calculate the decision that maximizes the probability
of survival at the specified time horizon; in this case, one year.
Of course, we do not live in a world of unlimited financial
resources, and so the decision must, to some degree, be made
in the context of cost. Comparing the relative cost and effec-
tiveness is called cost-effectiveness analysis, and requires an
appropriate measure of effectiveness.
[Vol. 7:163
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Often, mortality is not the relevant endpoint. For example,
whether to prescribe antibiotics before the result of a throat
culture for streptococcal infection is known would not be based
primarily on reducing mortality. Sometimes, the endpoint can
be captured in some other objective form of effectiveness, such
as the number of bedridden days, or the number of additional
cancers detected. When we divide cost by effectiveness we
obtain a cost-effectiveness ratio. Although it is common for the
cost-effectiveness ratio to be used as the yardstick to measure
different interventions, there is an important adjustment that
should be made.
Medical interventions strive either to prolong life or to
improve the quality of life. What is needed for more complete
evaluation is a measure that incorporates length of life and any
factors a patient may deem important in evaluating the quality
of life in a given health state. The approach that has been most
prevalent, and the approach that is recommended by the United
States Public Health Service's Panel on Cost-Effectiveness in
Health and Medicine2 is to use a quantity known as Quality
Adjusted Life Years (QALYs). This approach requires the
valuation of the possible health states on a scale from zero to
one, with one being perfect health and zero being death. This
value is called a utility (a term borrowed from consumer eco-
nomics) and represents a patient's preferences. This allows
incorporation of not only the patient's health state, but also
his/her overall quality of life. The utility score serves as a
"weight" for the health state. The time spent in a health state is
multiplied by the utility to produce a value that is expressed in
terms of an equivalent amount of time in perfect health. For
example, if life with mild arthritis is valued at 0.9, then one
year with mild arthritis is considered to be equivalent to nine-
tenths of a year of perfect health. In the case of breast cancer,
for example, we will need to value life after mastectomy in-
cluding all of the associated physical and emotional aspects.
Through the use of utilities, tradeoffs of length of life for qual-
ity of life can be evaluated. Competing medical interventions
are then compared on the basis of the additional cost incurred
2. See MARTHA R. GOLD ET AL., COsT-EFFEcTIvENEss IN HEALTH AND MEDICINE 308
(1996).
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to purchase an additional year of perfect health.3
Sensitivity analysis consists of asking "what if' questions.
A one-way sensitivity analysis involves changing the value of a
single parameter, such as the cost of an operation, while hold-
ing all other values in the model constant. The results are com-
pared to those obtained with the original, baseline values to
establish how sensitive the decision is to changes in the param-
eters. This is particularly critical in problems where some of
the information is not known with great certainty. A wide
range of values can be tested (covering reasonable lower and
upper bounds) and if the decision is not sensitive to these
changes, then a more precise estimate may not be required to
make a confident decision. If small changes to the input value
result in a different recommendation, then precise estimates of
this value are required before a conclusion can be drawn. Sen-
sitivity analysis can be used to identify those areas of uncer-
tainty that are likely to have an impact on the decision. This
can be used to set research priorities.
II. A DECISION TREE FOR BRCA1 TESTING
To develop a decision model for BRCA1 testing, the
choices and possible outcomes must be outlined. The initial
decision is whether to be tested for a BRCA1 mutation. This
might be a relatively simple test for the 185delAG deletion for
which Ashkenazi Jews are at particular risk,4 or it might be a
more complex test for any clinically important mutation of the
BRCA1 gene. After this decision is made, and the test results,
if taken, are known, there is a choice of what to do in the
3. See generally George W. Torrance, Measurement of Health State Utilities for Eco-
nomic Appraisal: A Review, 5 J. HEALTH ECON., Fall 1986, at 1 (detailing methodologies for
health state economic appraisals); George W. Torrance & David Feeny, Utilities and Quality-
Adjusted Life Years, 5 INT'L J. TECH. ASSESSMENT HEALTH CARE 559 (1989) (providing an in-
depth discussion of utilities and QALYs); George W. Torrance, Utility Approach to Measuring
Health-Related Quality of Life, 40 J. CHRONIC DISEASE 593 (1987) (providing an in-depth discus-
sion of measuring utilities). For a general methodology of cost effectiveness analysis, refer to
MICHAEL F. DRUMMOND ET AL., METHODS FOR THE ECONOMIC EVALUATION OF HEALTH CARE
PROGRAMMES (1987); FRANK A. SLOAN, VALUING HEALTH CARE: COST, BENEFITS, AND
EFFEcnIvENESS OF PHARMACEtrCALS AND OTHER MEDICAL TECHNOLOGIES (1995).
4. See Jeffrey P. Struewing et al., The Carrier Frequency of the BRCAJ 185delAG
Mutation is Approximately I Percent inAshkenazi Jewish Individuals, 11 NATURE GENETICS 198,
199 (1995).
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follow-up of the test results. Currently, the options are very
limited: Mrs. X may be offered a screening program which
would consist of some frequency of mammography and clinical
breast exam. She may have a prophylactic mastectomy or
tamoxifen. Or she may "watchfully wait." Regardless of the
patient's decision, she will be followed over time. She may
remain without disease or develop breast cancer at some point
in time. Breast cancer may progress through the four stages of
the disease before a patient either discovers the disease or
responds to treatment, if it is undertaken. The different health
conditions are called states, and the method for capturing the
movement between different health states over time is called a
Markov model. Inputs to the Markov model include the proba-
bilities for all possible transitions from one state to another,
and the cost and utility associated with being in a particular
health state for a given period of time. This is referred to as
the cycle time. Figure 2 depicts the basic decision model for
BRCA1 testing.
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A schematic representing the Markov model is shown in
Figure 3. It allows for health states corresponding to when a
patient is well, when a patient has each of the four stages of
breast cancer, and when a patient is dead. These are the choic-
es regardless of the path traversed in the model prior to enter-
ing the Markov model. However, the path leading to the
Markov model will affect the probabilities, costs, and utilities
inside the Markov model.
This is a basic model. The purpose of this Article is to
demonstrate how decision analysis can be employed to deal
with the complex issue of whether an individual should under-
go BRCA1 testing. Accordingly, the model presented is simpli-
fied to allow for easier understanding and discussion of its
components.
There are many alternative models that could be formulat-
ed. Screening programs for breast cancer come in many forms.
For example, the frequency of clinical breast exam could be
six months or one year. It may or may not be done in combi-
nation with annual or biannual mammography. Other technolo-
gies could be considered in place of mammography.
Following prophylactic mastectomy, there could be an
allowance for various screening options. Additionally, there
[Vol. 7:163
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was an attempt to include only commonly used interventions.
A notable exception is tamoxifen, because there is some evi-
dence to suggest that tamoxifen may have preventive value.'
In the interest of simplicity, prophylactic oophorectomy
(removal of the ovaries) is not included in the model presented
here. At this time, it is not known how much prophylactic
oophorectomy reduces the chance of breast cancer among
women with family history of breast cancer.6 Estrogen replace-
ment often is prescribed to treat the significant side effects that
often accompany the abrupt onset of menopause caused by
prophylactic oophorectomy in premenopausal women. It is not
known how much the effectiveness of prophylactic
oophorectomy is reduced by estrogen replacement therapy
Another issue that is not dealt with explicitly in this model
is the issue of timing. An individual will make a decision
appropriate for her current age and situation, but will need to
reevaluate this decision periodically. As is discussed later,
when a person passes menopause, her chance of breast cancer
increases, but the probability of a genetic-based breast cancer
decreases. Thus, the value of preventive measures or height-
ened screening increases, but the value of a BRCA1 test de-
creases. The model discussed here will deal with an individual
person, with her own unique risk profile for a given point in
time.
In order to perform the decision analysis, the associated
probabilities, costs, and utilities must be estimated. The com-
plexity involved is masked by the relative simplicity of the
decision tree. In particular, there are numerous factors that
must be accounted for in determining the probabilities and
utilities. The following sections will discuss the different com-
ponents of the decision tree and the current state of knowledge
about the probabilities, costs, and utilities, and what is involved
in obtaining these numbers.
5. See Susan G. Nayfield et al., Potential Role of Tamoxifen in Prevention of Breast
Cancer, 83 J. NAT'L. CANCER INST. 1450, 1452 (1991) (citing the length of time tamoxifen has
been used as a treatment for breast cancer).
6. See Mary-Claire King et al., Inherited Breast and Ovarian Cancer: What are the Risks?
What are the Choices? 269 JAMA 1975, 1979 (1993) (discussing the complexity of prophylactic
mastectomy).
7. Id.
1997]
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A. Risk of Breast Cancer
The results of this decision analysis are likely to depend
upon the probability of developing breast cancer. When consid-
ering the overall population, it is a simple matter to use exist-
ing epidemiologic data to estimate this. Current estimates of
the chance of breast cancer by age eighty-five are approximate-
ly one in nine, with a lifetime risk of one in eight.8 These esti-
mates can be used for the general population in the absence of
knowledge specific to the individual. However, in a decision
model for BRCA1 testing, estimates of the risk of breast can-
cer will be needed based on: 1) BRCA1 status: positive, nega-
tive, or untested; and 2) the presence of other risk factors,
especially family history. Carrier status will only be known
according to the degree of accuracy of the gene test, which
will be discussed later. Models have been developed by Eliza-
beth B. Claus, et al.9 and Mitchell H. Gail, et al. 0 that esti-
mate the probability of breast cancer based on family history
alone. According to the Claus model," a patient with one first
degree relative who had breast cancer diagnosed between forty
and forty-nine years of age, would have a thirteen percent
chance of breast cancer by age eighty, contrasted with a proba-
bility of 10.4% in the general population.' 2 Likewise, if the
first degree relative's cancer was diagnosed between the ages
of twenty and twenty-nine, the chance increases to twenty-one
percent. 3 Finally, having two first degree relatives diagnosed
between forty and forty-nine, raises the risk to thirty-five per-
cent.'
4
8. See Eric J. Feuer et al., The Lifetime Risk of Developing Breast Cancer, 85 J. NAT'L
CANCER INST. 892, 892 (1993) (citing statistical references for calculating lifetime risk of breast
cancer).
9. See generally Elizabeth B. Claus et al., Autosomal Dominant Inheritance of Early-
Onset Breast Cancer, 73 CANCER 643, 643-50 (1994) (describing a population-based, case-
controlled study to provide age-specific risk estimates of breast cancer for women with a family
history of breast cancer).
10. See generally Mitchell H. Gail et al., Projecting Individualized Probabilities of
Developing Breast Cancer for White Females Who are Being Examined Annually, 24 J. NAT'L
CANCER INST. 1879 (1989) (presenting a method to estimate the chance that a woman with a
given age and risk factors will develop breast cancer over a specified interval).
11. See Claus et al., supra note 9, at 645.
12. See Feuer et al., supra note 8, at 894.
13. See Claus et al., supra note 9, at 645.
14. See id. at 646.
[Vol. 7:163
DECISION-MAKING ANALYSIS
It is particularly difficult to estimate the probability of
breast cancer when taking into account the results of a BRCA1
test. Using a model based on analysis of 214 families, D.F.
Easton, et al. 5 estimated that BRCA1 carriers have a fifty-
nine percent chance by age fifty and an eighty-two percent
chance by age seventy of developing breast or ovarian cancer.
However, these numbers were based on families with multiple
affected individuals. In other words, these probabilities are for
people considered to have an extremely high risk of breast
cancer prior to any knowledge concerning BRCA1 status. It is
not yet known what the risk of breast cancer is among BRCA1
carriers with limited or no family history of breast cancer. 6
The role of other genetic and environmental factors is easily
overlooked when focusing on a single gene. 7 At this point in
time, the excess risk due to carrier status remains unclear.
It also is unclear if the disease progresses differently in
BRCA1 carriers. BRCA1 carriers are at increased risk of ovari-
an cancer, as well as breast cancer. 8 Recent evidence sug-
gests that BRCA1 carriers who develop ovarian cancer may
fare better than noncarriers of similar age and disease. 9 It is
not known if this same benefit might extend to breast cancer.
It has been stated that noncarriers (those with a negative
test for BRCA1) have a risk equivalent to the general popula-
tion," thus "canceling" the effect of family history. However,
15. D. F. Easton et al., Genetic Linkage Analysis in Familial Breast and Ovarian Cancer:
Results from 214 Families, 52 AM. J. HUM. GENETICS 678, 678 (1993) (relating findings of the
study).
16. See Michael G. FitzGerald et al., Germ-Line BRCAl Mutations in Jewish and Non-Jew-
ish Women with Early-Onset Breast Cancer, 334 NEw ENG. J. MED. 143, 148 (1996) (explaining
that more studies will have to be performed to determine the exact penetration of the allele of the
BRCA1 gene); Streuwing et al., supra note 4, at 199 (describing the Ashkenazic carrier rates for
the BRCAI 185delAG mutation); Heather Bryant, Genetic Screening for Breast Cancer in
Ashkenazi Women, 347 LANCET 1638, 1638 (1996) (commenting that the selected members of the
Ashkenazi population studied may not reflect the Ashkenazi population as a whole).
17. See Stephen H. Friend, Breast Cancer Susceptibility Testing: Realities in the Post-
Genomic Era, NATURE GENETICS, May 1996, at 16 (explaining that data suggests multiple factors
affecting breast cancer susceptibility).
18. See generally D. Ford et al., Risks of Cancer in BRCAI Mutation Carriers, 343 LANCEr
692,692-95 (1994).
19. See Stephen C. Rubin, Clinical and Pathological Features of Ovarian Cancer in
Women With Germ-line Mutations of BRCA1, 333 NEw ENG. J. MED. 1413, 1413-16 (1996)
(finding that cancers associated with BRCA1 mutations appear to have a significantly more
favorable clinical course).
20. See, e.g., Kent F. Hoskins et al., Assessment and Counseling for Women with a Family
1997]
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their risk should actually be slightly lower than that of the
general population because one risk factor, the BRCA1 muta-
tion, has been eliminated. The reduced risk due to a negative
test for BRCA1 is limited because the BRCA1 mutation is
estimated to account for only about seven percent of all breast
cancer cases.2' Although the Ashkenazi-Jewish community is
at higher risk for the 185delAG deletion, it is not yet known
whether they have a higher prevalence of BRCA1 mutations
overall. As pointed out by Lori S. Friedman, et al.,' such a
finding would be consistent with results suggesting a higher
proportion of inherited breast cancer in the Ashkenazi Jewish
population.' If this is the case, the benefit of a negative test
would be greater for Ashkenazi-Jews than for the general pop-
ulation.
B. Screening for Breast Cancer
There are numerous cost-effectiveness analyses in the
literature which address breast cancer screening.24 They are an
History of Breast Cancer, 273 JAMA 577, 581 (1995) (calculating the risk of developing breast
cancer with respect to BRCAI and BRCA2 in mutation carriers, noncarriers, and the general
population); Donna Shattuck-Eidens et al., A Collaborative Survey of 80 Mutations in the BRCAI
Breast and Ovarian Cancer Susceptibility Gene, 273 JAMA 535, 541 (1995) (stating that at-risk
women who do not inherit the BRCA1 mutation have the same risk of breast and ovarian cancer
as the general population); Mary-Claire King et al., supra note 6, at 1977 (stating that the lifetime
risk of breast cancer for both noncarriers and women in the general population of the United
States is approximately 10%).
21. See Elizabeth B. Claus et al., The Genetic Attributable Risk of Breast and Ovarian
Cancer, 77(11) CANCER 2318,2318 (1996).
22. Lori S. Friedman et al., Novel Inherited and Variable Expressivity of BRCA1 Alleles,
Including the Founder Mutation 185delAG in Ashkenazi-Jewish Families, 57 AM. J. HUM.
GENEICS 1284, 1294 (1995) (suggesting a higher proportion of inherited breast cancer in the
Ashkenazi-Jewish population).
23. See Susan P. Helmrich et al., Risk Factors for Breast Cancer, 117 AM. J. EPIDEMI-
OLOGY 35, 44 (1983) (finding that Jewish women are at a greater risk of getting breast cancer);
Jennifer L. Kelsey et al., Exogenous Estrogens and Other Factors in the Epidemiology of Breast
Cancer, 67 J. NAT'L CANCER INST. 327, 331 (1981); K. Egan et al., Jewish Religion and Risk of
Breast Cancer, 347 LANCET 1645, 1645 (1996).
24. See, e.g., Martin L. Brown & Lou Fintor, Cost-Effectiveness of Breast Cancer Screen-
ing: Preliminary Results of a Systematic Review of the Literature, 25 BREAST CANCER RES. &
TREATMENT 113, 113-18 (1993); Jeanne S. Mandelblatt et al., Breast Cancer Screening for
Elderly Women With and Without Comorbid Conditions, 116 ANNALS INTERNAL MED. 722,724
(1992); David M. Eddy, Screening for Breast Cancer, Ill ANNALS INTERNAL MED. 389, 389-99
(1989); Alvin . Mushlin & Lou Fintor, Is Screening for Breast Cancer Cost-Effective? 69
CANCER 1957, 1959-61 (Supplement 1992); Anthony B. Miller et al., Canadian National Breast
Screening Study: Breast Cancer Detection and Death Rates Among Women Aged 40 to 49 Years,
147(10) CAN. MED. ASs'N J. 1459, 1459 (1992); Ichiro Okubo et al., Cost-Effectiveness of Mass
[Vol. 7:163
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excellent source of data, although some of the models were not
based on data from the United States, and some data are based
on Medicare reimbursement rates which will not apply to
younger women. The structure of these models can form the
basis for the screening component of the model presented here.
However, these models have all been developed for the general
population. Thus, the probabilities will have to be modified to
take into account information specific to Mrs. X, such as her
risk profile.
C. BRCA1 Testing
There are many issues concerning BRCA1 testing that
must be considered in the decision model. These may be cate-
gorized as follows:
1. Accuracy of the test
2. Probability of a positive test
3. Cost of testing (including education and counseling)
4. Emotional effect of a positive test on the patient
5. Emotional effect of a negative test on the patient
6. Effect of a positive test on compliance with screening
7. Effect of a negative test on compliance with screening
Accuracy of medical tests may be characterized by the
rate of false negative and false positive test results, i.e., the fre-
quency with which true carriers are missed or true noncarriers
are falsely identified as carriers. Currently, there are no pub-
lished data for accuracy of testing for the known mutations of
BRCA1, let alone those that have yet to be discovered. Donna
Shattuck-Eidens, et al.' comments that the variety of methods
used and the heterogeneity of the patient samples with regard
to family history make it virtually impossible to ascertain the
accuracy of testing for BRCA1 mutation. Kent F. Hoskins, et
al. notes that once a BRCA1 mutation has been identified in a
Screening for Breast Cancer in Japan, 67 CANCER 2021, 2021-29 (1991); C. John Rosenquist &
Karen K. Lindfors, Screening Mammography in Women Ages 40-49 Years: Analysis of Cost
Effectiveness, 191 RADIOLOGY 647, 647-50 (1994); Martin L. Brown, Sensitivity Analysis in the
Cost-Effectiveness of Breast Cancer Screening, 69 CANCER 1963, 1963-66 (1992).
25. Shattuck-Eidens et al., supra note 20, at 541.
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family, screening for the specific mutation in other family
members is not complicated, but the complexity in identifying
the mutation for the first time in a family cannot be underesti-
mated.26 Looking for the 185delAG mutation, however, should
be more accurate because a specific mutation, especially a
deletion, is easier to detect.27 However, other mutations in
BRCA1, that are not deletions, will be more difficult to detect.
This could potentially result in more false negatives. Testing
for other mutations will also result in more false positives, due
to the difficulty of judging whether or not the mutation is
clinically significant.
The probability of an individual inheriting the trait from a
carrier parent is fifty percent.28 Thus, given information about
the probability of the parent having the trait, we can estimate
the probability of a particular child being a carrier.
Jeffery P. Struewing29  found a .9% prevalence of
185delAG deletion in the general Ashkenazi population. How-
ever, the results of Kenneth Offit, et al.3" suggest a somewhat
lower figure. Studies have shown that about twenty percent of
early-onset breast cancer patients in the Ashkenazi population
have this particular mutation,3' as opposed to a rate of about
eight percent in the non-Jewish population for any BRCA1
mutation.32 These studies provide a reasonable basis for esti-
mating the probability of a positive test for this particular
BRCA1 mutation.
26. Hoskins et al., supra note 20, at 581.
27. See Shattuck-Eidens et al., supra note 20, at 541.
28. See King, supra note 6, at 1976.
29. Struewing et al., supra note 4, at 148.
30. Kenneth Offit et al., Germline BRCAJ 185deAG Mutations in Jewish Women with
Breast Cancer, 347 LANCEr 1643, 1644 (1996) (stating that Struewing et al.'s figures (for the
citation see Struewing et al., supra note 4) may be higher because of the bias toward probands
with family histories of cancer).
31. See Offit et al., supra note 30, at 1644 (explaining that the 185delAG gene has an
estimated incidence of 22% and an actual incidence of 20%); FitzGerald et al., supra note 16, at
143 (explaining that the 185delAG gene is a detectable trait in 21% of Ashkenazi-Jewish women
who were treated as early-onset breast cancer patients).
32. See FitzGerald et al., supra note 16, at 147-48 (stating that 2/26 of the non-Jewish
population has this mutation).
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D. Cost of Testing
The Genetics and I.V.F. Institute in Fairfax, Virginia, for a
fee of $295, has been testing specifically for the 185delAG
mutation.33 Likewise, in October of 1996, Myriad Genetics,
Inc., of Salt Lake City, Utah, announced the introduction of
"BRCAnalysis (tm)."34 The charge is $2400 for a comprehen-
sive sequence analysis of BRCA1 and BRCA2.35 Once a mu-
tation has been identified in a family, additional family mem-
bers can be tested for that particular mutation for $395.36 In
addition, the cost of pre-test education and counseling must be
considered.
E. Emotional Impact of Testing
What emotional effect does the test result have on the
patient? Caryn Lerman, et al.3' found that noncarriers (those
with a negative test) showed statistically significant reductions
in depressive symptoms and functional impairment compared
with carriers and nontested individuals. Thus, a negative test
result may provide sufficient reassurance value to effect im-
provements in quality of life. Likewise, in this particular study,
carriers did not show any adverse effects after a positive
test.38 However, this failure to detect a decrease in quality of
life in people who tested positive may be misleading because
the population sampled consisted of people from families with
high family history of breast and ovarian cancer.39 Since they
knew they were at great risk for breast cancer, the positive test
result did not significantly change their situation. It is note-
worthy that only forty-three percent of the people tested were
33. See Gina Kolata, Breaking Ranks: Lab Offers Test to Assess Risk of Breast Cancer,
N.Y. TIMES, Apr. 1, 1996, at A1.
34. Myriad Genetics Introduces the First Comprehensive BreastlOvarian Cancer Suscep-
tibility Test, (visited Nov. 31 1996) <hhtp://www.myriad.com/Launch%20PR>.
35. See id.
36. See id.
37. Caryn Lerman et al., BRCAI Testing in Families With Hereditary Breast-Ovarian
Cancer, 275 JAMA 1885,1885,1887 (1996) (administering the Center for Epidemiologic Studies
for Depression Scale during the baseline and follow-up interviews to assess depressive
symptomatology).
38. See id.
39. See id. at 1886.
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interested in knowing their result.' Thus, for those who did
not want their test results, it may be that they did in fact asso-
ciate a significant reduction in quality of life with a positive
test result and that was the basis for their decision.
F. Impact of Test Results on Subsequent Compliance
Another important issue in relation to BRCA1 testing is
the effect it might have on compliance with mammographic
screenings and clinical breast exams. It has been well-estab-
lished that compliance with screening is correlated with per-
ceived risk.4' This especially is true with younger women.42
Although many women may be reluctant to participate due to
cancer anxiety, compliance is generally improved when the
patient is aware of the risk.43 At this point, it is too soon to
have any evidence of compliance after individuals learn the
results of genetic testing. Will people with a positive test be
more diligent in following through with an increased level of
screening? Will people with a negative test have a tendency to
think that they are "off the hook?" As the vast majority of
breast cancers are not genetic in origin, noncarriers must be
told that they still need to follow-through with regular screen-
ing at the appropriate ages. Since the effectiveness of mam-
mography prior to age fifty is in question," will a younger
woman choose to postpone screening until then? Will the "re-
lief' of the negative test wear off by then, thus having no ef-
fect on compliance? The issue of the effect of the test result on
40. See id. at 1888 (indicating that 57% did not want to know the test results).
41. See Victoria Lee Champion, The Relationship of Selected Variables to Breast Cancer
Detection Behavior in Women 35 and Older, 18 ONCOLOGY NURSING 733, 735-36 (1991)
(describing the relationship between selected variables and the practice of breast self-
examination); Stephen Taplin et al., Breast Cancer Risk and Participation in Mammography
Screening, 79 AM. J. PUB. HEALTH 1494, 1494 (1989) (stating that women in a high-risk group
for breast cancer are the most likely to participate in mammographic screening).
42. See Taplin et al., supra note 41, at 1496.
43. See Kathryn M. Kash et al., Psychological Distress and Surveillance Behaviors of
Women with a Family History of Breast Cancer, 84 J. NAT'L CANCER INST. 24, 27 (1992)
(finding a negative relationship between cancer anxiety and regular clinical breast examination).
44. See Anthony B. Miller et al., supra note 24, at 1460 (stating that yearly mammography
and physical examination of breasts detected considerably more node-negative, small tumors than
usual care, but had no impact on the rate of death from breast cancer); Rosenquist & Lindfors,
supra note 24, at 649-50 (stating that reduction in mortality results from screening mammography
in women between the ages of forty and forty-nine remains unknown).
178 [Vol. 7:163
DECISION-MAKING ANALYSIS
compliance with screening is purely speculative at this time. In
the context of a decision analysis, this could be handled in the
sensitivity analysis. Likewise, if it turns out that the decision to
be tested is insensitive to this parameter, then it would be
unnecessary to obtain a precise estimate of the effect of test
status on compliance with screening.
G. Prophylactic Mastectomy
The only established prophylactic option currently avail-
able is a mastectomy. Historically, the most common procedure
is a subcutaneous mastectomy. Though this procedure leaves
behind about five percent of the breast tissue, it yields a much
better cosmetic result than total mastectomy. Subcutaneous
mastectomy is not one-hundred percent successful as there
have been cases of breast cancer reported in patients who have
had subcutaneous mastectomy.45 To date, there have been no
epidemiologic studies of the effectiveness of prophylactic mas-
tectomy. Animal studies have failed to find significant benefit,
let alone a guarantee.' In all of these studies, complete mam-
mectomy was not possible and the residual breast tissue was at
45. See David G. Bowers Jr. & Charles B. Radlauer, Breast Cancer After Prophylactic
Subcutaneous Mastectomies and Reconstruction with Silastic Prostheses, 44 PLASTIC &
RECONSTRUCTIVE SURGERY 541, 541-42 (1969) (detailing two cases of breast cancer occurring
after prophylactic subcutaneous mastectomies); Miguel A. Mendez-Femandez et al., Paget's
Disease of the Breast After Subcutaneous Mastectomy and Reconstruction With a Silicone
Prosthesis, 65 PLASTIC & RECONSTRUCTIVE SURGERY 683, 683 (1980) (detailing a case where
Paget's Disease occurred after subcutaneous mastectomy); Vincent R. Pennisi & Angelo Capozzi,
The Incidence of Obscure Carcinoma in Subcutaneous Mastectomy, 56 PLASTIC &
RECONSTRUCTIVE SURGERY 9, 10 (1975) (discussing the results of a national survey which led to
the belief that subcutaneous mastectomy is the most effective procedure available for women with
a high-risk of developing breast cancer); Walley J. Temple et al., Technical Considerations for
Prophylactic Mastectomy in Patients at High Risk for Breast Cancer, 161 AM. J. SURGERY 413,
413 (1991) (documenting an incidence of breast cancer in follow-up reports of prophylactic
mastectomy cases).
46. See Christopher F. Jackson et al., The Effectiveness of Prophylactic Subcutaneous
Mastectomy in Sprague-Dawley Rats Induced with 7,12-Dimethylbenzanthracene, 73 PLASTIC &
RECONSTRUCTIVE SURGERY 249, 254 (1984) (detailing experiment showing no benefit from
prophylactic subcutaneous mastectomy in Sprague-Dawley rats); Jan H. Wong et al., Analysis of
the Risk Reduction of Prophylactic Partial Mastectomy in Sprague-Dowley Rats with 7, 12-
Dimethyl Benzanthracene-Induced Breast Cancer, 99 SURGERY 67, 67 (1986) (detailing
experiment showing no significant difference in number of tumors among groups given varying
degrees of partial mastectomy); Heidi Nelson et al., Effectiveness of Prophylactic Mastectomy in
the Prevention of Breast Tumors in C3H Mice, 83 PLASTIC & RECONSTRUCTIVE SURGERY 662,
662 (1989) (concluding that mammary tumor incidence was not decreased, even by 100%
mammectomy).
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increased risk of cancer.47 However, it is well-accepted that
not all of the breast tissue is removed by total mastectomy in
humans,' and the remaining breast tissue may be at increased
risk.
Florence Houn, et al. studied the recommendations and
performance of prophylactic mastectomy in Maryland.49 Prac-
tice patterns varied significantly across specialty, not only in
terms of a risk threshold before performing prophylactic mas-
tectomy, but also in terms of the type of mastectomy (subcuta-
neous or total)." Florence Houn, et al. conclude that there is a
need for better evaluation of the efficacy and appropriateness
of prophylactic mastectomy.5' Certainly, in terms of doing a
proper decision analysis a reasonable figure for recurrence of
breast cancer after prophylactic mastectomy is needed. Rates of
0.5 percent52 and one percent53 in short term follow-up after
subcutaneous mastectomy have been cited. However, these
numbers cited must be taken in the context of the likelihood of
breast cancer before the mastectomy. Thus, the rate of breast
cancer after mastectomy is not known, and screening may still
be needed.
Cost of prophylactic mastectomy varies greatly depending
on the type of mastectomy performed and the amount of recon-
struction. This amount can range from $5,000-$50,000. 54
The issue of utility of prophylactic mastectomy is ex-
tremely complex. Utility measures must model not only the
patient's perception of her medical well-being, but also her
emotional well-being. In essence, it is a measure of quality of
life. In this case, beyond the usual issues of health risk, func-
tional status, and personal attitude, there are many "outside"
factors that may play a very significant role. These include the
47. See Nelson, supra note 46, at 666.
48. See id.; King, supra note 6, at 1979.
49. Florence Houn et al., The Practice of Prophylactic Mastectomy: A Survey of Maryland
Surgeons, 85 AM. J. PUB. HEALTH 801, 804-05 (1995).
50. See id.at 801.
51. Id.
52. See Pennisi & Capozzi, supra note 45, at 9-10 (relying on a questionnaire with a 44%
response rate that included a mix of risk factors (many low-risk patients)). Furthermore, this data
may be out of date.
53. See Temple et al., supra note 45, at 413 (relying on anecdotal reports).
54. See Hoskins et al., supra note 20, at 583.
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following: 1) cultural attitude; 2) religious beliefs; 3) spouse's
attitude; 4) marriageability; 5) insurability; and 6) potential
employment discrimination. Jane Hall, et al. summarizes sever-
al reports that deal with utility of mastectomy.55 Of particular
importance are the findings that psychological aspects outweigh
the physical, and that women with breast cancer assigned high-
er utilities than potential patients. 6 In light of these findings,
it is very unclear how to extend these results to the case of
prophylactic mastectomy. The extreme complexity of the non-
physical issues require investigation. It may be that the role of
non-physical factors will be more extreme in prophylactic
treatment. Cultural or spousal attitudes may be much less ac-
cepting of mastectomy as a response to risk of breast cancer as
opposed to mastectomy as a treatment for the development of
breast cancer. In the context of a decision analysis, this utility
will be contrasted with the utility of living with the risk of
breast cancer of the individual patient. However, the risk of
breast cancer is itself an important factor in determining the
utility. Thus, BRCA1 carrier status would be expected to be an
important factor in the utility of prophylactic mastectomy.
Religious beliefs may also be a factor. In the case of
Ashkenazi women, following a rabbinic ruling may provide a
sense of comfort. Likewise, not following it may cause feelings
of "guilt." There is a great need to better understand the role of
the many important non-physical factors in the utility of pro-
phylactic mastectomy. For now, the limited utilities available
can be used as baseline values, with sensitivity analysis to
allow for a wide range of utilities. However, because a patient
at risk for genetic breast cancer will be considering prophylac-
tic mastectomy at an early age, thus spending many years in a
post-mastectomy state, the model may be very sensitive to this
utility.
55. Jane Hall et al., A Lost Utility Analysis of Mammography Screening in Australia, 34
SOC. SC. MED. 993, 1001-03 (1992) (summarizing cost utility reports related to mastectomy to
determine the utility of mastectomy and other medical interventions that are implemented as a
result of breast cancer).
56. See id.
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H. Tamoxifen
Tamoxifen has been used as a treatment for breast cancer
for over twenty years.17 Used as an adjuvant therapy for early-
stage breast cancer, it has been associated with a thirty-five
percent decrease in developing a second primary tumor in the
contralateral breast.58 This suggests a preventive effect, and as
a result, there are clinical trials in progress which are exam-
ining use of tamoxifen in a preventive setting. Although
tamoxifen has been in use since the early 1970s, the benefits
and risks associated with its long-term use by younger, high-
risk women is unknown.59 Likewise, use as a preventive drug
outside of the trial might be considered inappropriate.' Insur-
ance coverage would be unlikely, and the cost is significant.
Tamoxifen has a low incidence of side effects." Howev-
er, it has been associated with depression, thrombotic events,
and several forms of cancer, including endometrial, hepatic,
and possibly liver cancer.62
Given the success of tamoxifen in preventing second pri-
mary cancers, and its demonstrated chemopreventive and/or
chemosuppressive activity in rodent models,6" there is much
hope for this drug. At this point, however, its efficacy in the
preventive setting is not known. This is particularly true for
premenopausal women who have been underrepresented in
clinical trials that studied the prevention of contralateral breast
cancer.' At this point, there does not seem to be a basis for
57. See Nayfield et al., supra note 5, at 1450 (stating that benefits of tamoxifen include
overall survival as well as disease-free survival for women over age fifty).
58. See id. at 1452 (citing statistics relating to the efficacy of tamoxifen in preventing
second primary tumors in the contralateral breast).
59. See King, supra note 6, at 1979 (clarifying that as part of a randomized controlled
study, questions of risk can be clarified and tamoxifen's role in prevention can be determined for
women in general).
60. See id.
61. See Nayfield et al., supra note 5, at 1451 (indicating that tamoxifen may have a
potential role in chemoprevention of breast cancer in healthy women with increased risk of
disease).
62. See id. at 1455-56 (stating that the estrogenic effects of tamoxifen may be dose
dependant and related to duration of therapy).
63. See id. at 1451 (stating that tamoxifen is associated with approximately a 35% decrease
in contralateral breast tumors for women with early-stage breast cancer in the adjuvant setting).
64. See id. at 1452 (suggesting that because there is a strong inverse association between
age and risk of contralateral breast cancer, premenopausal patients may experience greater risk
reduction with adjuvant tamoxifen therapy than postmenopausal women).
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estimating the effectiveness of tamoxifen in prevention. As
results from the prevention trials become available, they can be
incorporated into the decision model.
I. Genetic Discrimination
A person who tests positive for a BRCA1 mutation runs
the risk of some form of genetic discrimination. This may be
in the form of employment discrimination or impaired ability
to obtain certain types of insurance, such as life, health care, or
disability. The individual has some protection from the Reha-
bilitation Act of 197365 and the Americans with Disabilities
Act of 1990 (ADA),' as well as varying degrees of protection
from state laws.67
Genetic discrimination is still a new and relatively untest-
ed area of the law. A United States Supreme Court decision
seems to have defined a carrier of a susceptibility gene as
"disabled," thereby enabling that person to be covered by the
ADA.' Of particular importance is the extent that state anti-
discrimination laws cover insurance companies, an area largely
ignored by the ADA.69 Insurance companies routinely require
full disclosure of relevant matters that only the applicant may
know. Likewise, withholding this information could be
fraudulent." As genetic research continues to advance, oppor-
tunities for genetic discrimination will increase dramatically.
65. See generally The Rehabilitation Act of 1973 § 501, 29 U.S.C. 794 (Supp. V 1993).
66. See generally The Americans with Disabilities Act § 102, 42 U.S.C. § 12101-213
(Supp. V. 1993).
67. See Marvin R. Natowicz et al., Genetic Discrimination and the Law, 50 AM. J. HUM.
GENETICS 465, 471-72 (1992) (stating that although all states prohibit unfair discrimination by life
insurers and some states prohibit unfair discrimination by health insurers, in general, state law
provides minimal protection against genetic discrimination in the insurance field).
68. See Sch. Bd. of Nassau County v. Arline, 480 U.S. 273,284 (1987).
69. See Natowicz et al., supra note 67, at 471, 473 (stating that the greatest weakness of the
ADA is the exception it provides for insurance companies).
70. See Bernard M. Dickens et al., Legal and Ethical Issues in Genetic Testing and Coun-
selling for Susceptibility to Breast, Ovarian and Colon Cancer, 154(6) CAN. MED. Assoc. J. 813,
816 (1996) (stating that insurance companies expect that applicants who have genetic test results
will disclose them and that nondisclosure could render the contract voidable even if death or dis-
ability is unrelated to the undisclosed risk); Maxwell J. Mehlman et al., The Need for Anonymous
Genetic Counseling and Testing, 58 AM. J. HuM. GENETICs 393,394 (1996) (stating that although
probands should be cautioned that withholding information could be fraudulent, the law is
evolving in terms of whether employers and insurers even have the right to ask for this
information).
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Thus, present and future laws that cover genetic discrimination
will be tested. The potential for genetic discrimination, and the
great uncertainty about its future effects, contribute significant-
ly to a woman's assessment of the utility of a positive BRCA1
test.7' Also, the possibility of restricted access to health care
insurance could have adverse effects on decisions concerning
therapeutic and prophylactic alternatives, as well as their costs.
111. OTHER ISSUES
The role of insurance may be extremely important. Pro-
phylactic mastectomy (especially with reconstruction) and long-
term use of tamoxifen are both expensive options. Given the
limited knowledge of effectiveness, it is questionable how
many insurers would pay for these treatments. As more data
become available, and the marketing value of being perceived
as sensitive to women's health needs is re-analyzed, many
insurers may choose to reevaluate whether to cover such treat-
ments.
An important component of any decision analysis is the
perspective adopted. Although the model here has been dis-
cussed from the perspective of the patient, it also can be
looked at from the perspective of a governmental or private in-
surer. This would involve looking at risks for groups, rather
than individuals, and would also have a significant impact on
the cost numbers used in the model. Likewise, different popu-
lations can be analyzed separately to effectively consider the
different risk groups. However, many of the most complex
issues, such as the role of culture and religion on the decision
process, may be considered in modifying the utility scores. The
71. For a more complete discussion of discrimination, refer to Jean E. McEwen & Philip R.
Reilly, State Legislative Efforts to Regulate Use and Potential Misuse of Genetic Information, 51
AM. J. HUM. GENETICS 637, 637-47 (1992) (studying laws relating to confidentiality, informed
consent, discrimination, and related issues); Mehlman et al., supra note 70, 393-97 (proposing a
form of anonymous testing and counseling whereby personal information and test results would
be stored and released solely on the basis of a code); Natowicz et al., supra note 67, at 465-74
(discussing the applicability of various relevant federal and state laws in the areas of employment
and insurance discrimination); Dickens et al., supra note 70, at 813-18 (stating that traditional
ethical orientations and principles may be applied to genetic testing and counseling for
susceptibility to breast, ovarian, and colon cancer, but that female ethics will have particular
importance).
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prominent role of these factors, combined with the intensely
personal nature of the disease, provides a setting where the
parameters of the model may vary greatly among individuals.
IV. SUMMARY
The decision of whether an individual should be tested for
BRCA1 carrier status is multifaceted. The complex medical,
emotional, religious, social, and economic aspects make it
extremely difficult to reach an informed choice. Decision anal-
ysis is a methodology that can consider all of these aspects and
be customized to fit an individual's unique situation. Although
there is much uncertainty, sensitivity analysis will overcome
this limitation or identify those areas of uncertainty that require
further study.
There are many women who will not have the luxury of
waiting for more data before making a decision about BRCA1
testing. Decision analysis is a technique that physicians can use
to help their patients come to an informed choice.
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